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A B S T R A C T
The rates of cervical cancer (CxCa) in England among women aged 20–24 yrs increased from 2.7 in 2012 to 4.6
per 100,000 in 2014 (p = 0.0006). There was concern that the sudden increase was linked to the withdrawal of
cervical screening in women aged 20–24 (a policy that aﬀected women born since 1984).
We analyse granular data on age and FIGO stage at diagnosis using a generalised linear model to see whether
the unprecedented increase in CxCa in young women in 2014 was linked to the change in 2012 to the age at
which the ﬁrst invitation to screening was sent (from 25.0 to 24.5).
Annual rates of CxCa per 100,000 women aged 20.0–24.5 yrs decreased gradually over time, whereas at age
24.5–25.0 yrs they increased from an average of 16 pre-2013 to 49 in 2015. An increase of 20.3 per 100,000
women aged 24.5–25.0 yrs (95% CI: 15.2–25.4) was associated with inviting women for screening at age
24.5 yrs instead of at age 25.0. At age 25.0–25.5 yrs, rates decreased by 23.7 per 100,000 after women were
invited at age 24.5 yrs (p < 0.001). All these changes were limited to stage I CxCa. There was a dramatic
increase in diagnoses at age 25 yrs in 2009–2011 associated with changing the age at ﬁrst invitation from 20 yrs
to 25 yrs. No changes were observed at age 26.0–27.0 yrs.
The increase in CxCa aged 20–24 is attributable to an increase in the proportion of women ﬁrst screened aged
24.5 yrs. The increase was limited to stage I CxCa. There is no evidence of a lack of screening leading to in-
creasing rates.
1. Introduction
In 2004 the age of ﬁrst cervical screening invitation in England was
increased from 20 to 25 (Public Health England). This reﬂected a major
change in screening policy and was based on evidence that screening at
ages 20–24 provided no population beneﬁt in terms of cancer preven-
tion (Sasieni et al., 2003). In 2012, the age of sending out the ﬁrst
screening invitation was changed again; this time to 24.5 years. This
was simply to enable women to be screened by their 25th birthday as it
was noted that many women were only screened following a second
reminder up to 6 months after the initial invitation (Health and Social
Care Information Centre, 2013); it was not considered to be a major
policy change. Approximately 62% of women aged 25–29 attend
screening (Health and Social Care Information Centre, 2013). Amidst
these changes HPV vaccination was introduced in 2008 for girls aged
12–13 with catch-up for those aged 14–18. Many people expected CxCa
rates in women aged 20–24 to fall by 2014 as the vaccinated cohorts
entered their twenties. However, in 2016 national statistics showed a
worrying and substantial increase in the rate of cervical cancer (CxCa)
at ages 20 to 24 (from 2.7 in 2012 to 4.6 per 100,000 in 2014,
p = 0.006) (Oﬃce for National Statistics, 2016). Rates in this age group
had been stable until 2012. Rates of CxCa in England at ages 25–29
have been steadily increasing from around the time of the ﬁrst policy
change onwards (from 10 per 100,000 in 2003 to over 20 per 100,000
in 2014).
The sudden increase in CxCa in women aged 20–24 sparked con-
cerns that by withdrawing screening in 20–24 year olds, an epidemic
stemming from lack of prevention was starting to emerge. This was
particularly concerning as some argued that the lack of a reduction in
rates showed that HPV immunisation had been ineﬀective. This paper
describes an evaluation that was undertaken in response to these con-
cerns. The analysis explores trends in CxCa in women aged< 30 yrs
between 2006 and 2015, focussing on changes in the age at diagnosis
and FIGO stage, over time. The aim was to elucidate what factors are
driving the increase in cervical cancer among women aged 20–24 using
routinely collected incidence data.
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2. Methods
Notational convention: when we state the age in years without a
decimal such as 26 we mean≥26 and< 27. When we use an age range
including a decimal we mean≥ to the lower age and< the upper age.
Thus “20–24” is the same as “20.0–25.0”.
2.1. Data
We plotted trends based on routinely published Cancer Registration
Statistics for England from 1990 to 2015 (Oﬃce for National Statistics,
1990–2015); for Scotland from 1990 to 2014 from the Scottish Cancer
Registry (Information Services Division. NHS National Services, 2016);
for Wales data between 1990 and 2011 from the Welsh Cancer In-
telligence and Surveillance Unit (The Welsh Cancer Intelligence and
Surveillance Unit, 2013) and for cancers diagnosed between 2012 and
2015 from the Welsh Cancer Intelligence and Surveillance Unit website
(Welsh Cancer Intelligence and Surveillance Unit, 2016). To ascertain
the number of women invited for their ﬁrst screening test at ages 20–24
we used data from Table 4 of the KC53 Part B returns published in the
NHS Cervical Screening Programme Statistics, Source: KC53, Table 4
from 2010/11 to 2014/15 (Health and Social Care Information Centre
and Screening and Immunisations, 2016).
In addition, by special request, we obtained (from the National
Cancer Registration and Analysis Service, Public Health England) di-
agnoses of CxCa (ICD10 C53) in England by FIGO stage at diagnosis for
ages 20–29 with detailed breakdown of those occurring at age
24.5–25.0, 25.0–25.5 and those at 25.5–26.0 for 2006 to 2015. These
age ranges were chosen to examine in detail the eﬀect of sending
screening invitations six months earlier (i.e. at age 24.5 instead of at
age 25.0).
It should be noted that the date of diagnosis recorded by the cancer
registry should be the date on which the biopsy providing histological
conﬁrmation of the cancer was taken. HPV triage was introduced into
cervical screening in England in 2012–2013. Prior to that a borderline
(ASCUS) or mild (LSIL) smear would have been repeated at 6 months
and women were only discharged from 6-monthly testing after three
consecutive normal smears. Thus it could be 18 months or more from a
screening abnormality until referral for colposcopy and cancer diag-
nosis. With HPV triage women should either be referred to colposcopy
or returned to routine screening following their screen. National policy
is for women to be informed of their results of screening within
2 weeks; in 2014–15 about 90% met the target (fewer than 1% took
over 3 weeks) (Health and Social Care Information Centre, 2015). Time
from referral to colposcopy appointment varied depending on the se-
verity of cytology: 98% of high-grade cytology was oﬀered an ap-
pointment within 4 weeks, but it took 8 weeks to include 98% of all
referrals. Some clinics treat women with high-grade cytology at ﬁrst
colposcopy appointment, but most recall those with high-grade disease
on biopsy for subsequent treatment. National data show that 82% all
screen-detected cancers are diagnosed within four months of the
screening test that led to colposcopy referral (Sasieni and Castanon,
2014).
2.2. Assumptions
The change in policy from ﬁrst inviting women from age 20 to age
25 years was implemented in England over a 15-month period starting
in August 2004. Since we did not have the date at which an individual
was ﬁrst invited for cervical screening, it is not clear whether women
born between 26 August 1984 and 3 November 1985 were invited for
screening before age 25. We estimate year of birth using year of diag-
nosis minus age (in years) at diagnosis. We categorised all women born
before 1984 as ‘invited from age 20’, those born between 1986 and
1988 as ‘invited from age 25’. The change in policy inviting women at
age 25.5 was implemented in December 2012 therefore we categorise
women born from 1989 onwards as ‘invited from age 24.5’. Women
born in 1984 and 1985 were labelled ‘mixed group’ because they may
have either been invited from 20 or from 25 years.
We grouped FIGO stage as follows: Stage IA, Stage IB and Stage II or
worse. Since some women had a recorded FIGO stage of I without
further detail we proportionally distributed these cases between FIGO
IA and FIGO IB. Those women with an unknown FIGO stage at diag-
nosis were distributed proportionally between stages IB and II or worse.
We assume that those with missing stage were not stage IA because we
know from previous research using the Audit of Invasive Cancer
(Sasieni and Castanon, 2014) that women included in the Audit with
un-staged cancers who eventually have their cancers staged rarely had
stage IA cancer. We also performed a sensitivity analysis excluding
cases of unknown FIGO stage.
2.3. Statistics
Cancer rates by nation (England, Scotland, Wales) and ﬁve-year age
were smoothed against year of diagnosis using symmetric nearest
neighbour smoothing (using the ‘running’ command in STATA).
An age-period-cohort analysis was not considered because i) we
have little follow up for women invited from age 24.5, ii) we did not
have number of cancers in six monthly intervals for all age groups and
iii) not all cohorts reached age 30 by 2015. Instead a backward stepwise
generalised linear model using the Poisson family and identity link
function was ﬁtted to obtain the change in rates associated with the age
at screening invitation.
We include the following covariates in the regression: i) year of
diagnosis; ii) a dummy variable (1/0) to indicate diagnoses in 2009,
corresponding to the year in which reality TV star Jade Goody died.
There were about half a million extra attendances to screening in
England between her diagnosis (August 2008) and death (March 2009).
At its peak, in March 2009 attendance was 70% higher than usual
(Lancucki et al., 2012); iii) a variable to reﬂect the proportion of the
birth cohort aﬀected by the policy to screen from age 25.0 (X25 = 0 for
birth cohorts< 1984, =0.35 for 1984, =0.70 for 1985 and =1 for all
other cohorts); iv) a variable to reﬂect the proportion of the birth cohort
ﬁrst invited for screening at age 24.5 (X24 = 0 for birth cohorts<
1989, =0.75 for the 1989 cohort and =1 for all other cohorts). Note
that no woman has both X24 = 1 and X25 = 0. Sensitivity analyses on
the eﬀect of changing the proportion of women invited for screening in
the ‘mixed’ cohorts were carried out. For the comparison of stage at
diagnosis pre and post change in age at invitation we used a chi-square
statistic with two degrees of freedom. p values of< 0.05 were con-
sidered statistically signiﬁcant.
Data analyses were performed in STATA 13.1 (StataCorp.
1985–2013. Stata Statistical Software: Release 13.1. College Station,
TX, USA: StataCorp LP).
3. Results
3.1. Comparison between countries with diﬀerent policies
Comparison of incidence rates in England (where screening women
aged 20–24 yrs was phased out between 2004 and 2009) with rates in
Scotland and Wales (where screening from age 20 yrs continued until
after 2014) are presented in Fig. 1. Year-to-year variation in rates is
much greater in Scotland and Wales than in England reﬂecting the very
diﬀerent population sizes.
In England an increase in rates among 20–24 year old women is
evident from 2013 onwards. This coincides with an increase in the
number of women under age 25 invited for screening for the ﬁrst time
(reﬂecting the change in policy to send out invitation 6 months earlier)
from 35,435 invitations in 2010–11 to 189,544 in 2014–15, Table 1.
Cervical cancer rates for women aged 20–24 yrs in Scotland and Wales
have also increased over the last 10 years, Fig. 1. In fact, rates in
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Scotland in 2014 were as high as those in England. Rates at ages
25–29 yrs have increased in all three countries from around 2005 on-
wards; however those in England have seen the steepest rise.
3.2. Changes in the age at diagnosis of cervical cancer
Numbers of diagnoses and incidence rates of CxCa diagnosed in
England from 2006 to 2015 by age at diagnosis are presented in Fig. 2.
The ﬁgure is colour-coded to indicate the age (based on birth cohort) at
which women would have received their ﬁrst invitation for screening.
Details by age at diagnosis of the change in cancer incidence rates
(increase or decrease) per 100,000 women-years and their association
with calendar year, age at which women are ﬁrst invited for screening
and the Jade Goody eﬀect are shown is Table 2.
We observed a gradual decrease with calendar year in the rate per
100,000 women-years at age 20.0–24.5 yrs (annual decrease 0.08, 95%
CI 0.05 to 0.12, p < 0.001); diagnoses decreased from 37 in 2006 to
24 in 2015, Fig. 2A. On the other hand the number of cancers diagnosed
at ages 24.5–25.0 yrs increased suddenly from an average of 16 pre-
2013 (when women were ﬁrst invited either from age 20 or at age
25.0 yrs) to 49 in 2015 (when women were ﬁrst invited at 24.5 yrs),
Fig. 2B. The magnitude of the increase in rates at age 24.5–25.0 yrs
associated with inviting women at age 24.5 yrs was 20.3 per 100,000
women-years (95% CI: 15.2 to 25.4, p < 0.001), Table 2.
An even more dramatic increase in diagnosis of CxCa was observed
at age 25 yrs following the change in age at ﬁrst invitation. Diagnoses
increased four-fold between 2006–08 and 2010–12. The majority of the
increase in this age group is observed among women aged
25.0–25.5 yrs between 2006 (n = 17) and 2013 (n = 102), after which
the number diagnosed fell substantially (n = 54 in 2015) but are still
much greater than when screening was from age 20, Fig. 2C. Inviting
women at age 25.0 yrs was associated with an increase of 43.7 cancers
per 100,000 women-years (95% CI: 37.4 to 49.9, p < 0.001), Table 2.
Conversely the eﬀect of inviting women for screening six months earlier
(when they reach age 24.5 yrs) was to decrease incidence rates in
women age 25.0–25.5 yrs by 23.7 per 100,000 women-years (95% CI:
14.8 to 32.6, p < 0.001) relative to what was observed when ﬁrst
invitation was sent at age 25.0 yrs; equivalent to a reduction in rates
from about 51 to 27 per 100,000. However rates at age 25.0–25.5 are
still high compared to 9.7 per 100,000 observed in 2006.
The increase in CxCa at age 25.5–26.0 yrs between 2006 and 2013
was more moderate: annual diagnoses increased from an average of 18
to 46, Fig. 2D. Inviting women to screening at age 24.5 yrs had no eﬀect
on incidence rates at age 25.5–26.0 yrs. However inviting women at age
25.0 yrs was associated with an increase in rates of 14 per 100,000
women-years (95% CI: 9.9 to 18.1, p = 0.001). At 26 yrs of age there
was no signiﬁcant eﬀect of calendar year, age at ﬁrst invitation, or Jade
Goody on incidence rates (0.42, 95% CI: −0.02 to 0.86, p = 0.059),
Table 2 and Fig. 2E.
The increase in cervical screening in response to press coverage
regarding Jade Goody's diagnosis and subsequent death was associated
with a signiﬁcant increase in the number of cancers diagnosed in 2009
at ages 27–29 yrs, Fig. 2G–H and Table 2.
Women ﬁrst invited for screening at age 25.0 yrs had higher rates of
diagnoses at ages 28.0–29.0 yrs (most likely reﬂecting screen-detected
cancers diagnosed as a result of 3 yearly recall), Table 2. In particular,
at age 28 yrs, an increase in cancers of 13.7 per 100,000 (95% CI: 9.8 to
17.6, p < 0.001) was associated with the cohort being ﬁrst invited at
age 25.0 yrs.
Results from the sensitivity analyses on the proportion of women
invited at age 24.5 yrs (or 25.0 yrs) among women in the ‘mixed group’
did not signiﬁcantly change the results (data not shown).
3.3. Changes in the FIGO stage at diagnosis
To understand the clinical signiﬁcance of the increase in CxCa di-
agnosis we have looked at the FIGO stage at diagnosis among women
aged< 30 yrs, Fig. 3 and Table 3. Results restricted to women with
known FIGO stage are presented in Supplementary Table 1.
Following the ceasing of screening in women under age 25.0 yrs, the
Fig. 1. Cervical cancer incidence trends
1990–2015 by country in women aged 20 to
29 years.
Table 1
Number of women in England invited for screening for the ﬁrst time in the year by age,
2010–15.
Age group at
ﬁrst invitation
Number of women receiving their ﬁrst invitation to screening in
England by ﬁnancial year
2010/11 2011/12 2012/13 2013/14 2014/15
20–24 35,435 36,082 83,930 177,625 189,544
25–29 444,677 479,293 516,396 486,944 428,142
Total 480,112 515,375 600,326 664,569 617,686
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decrease in incidence rates with calendar time at age 20–24.5 was only
statistically signiﬁcant for stage IA cancers (p < 0.001). Among
women aged 24.5–25.0 yrs the increase in rates per 100,000 women-
years associated with inviting women at age 24.5 yrs was 15.5
(p < 0.001) for stage IA and 7.3 (p < 0.001) for stage IB. There were
fewer stage II or worse cancers in 2013–2015 in this age group than in
any year since 2007 (p = 0.001), Table 3.
Among women aged 25.0–25.5 yrs, receiving an invitation at age
25.0 yrs (rather than from 20 yrs) led to an increase in stage IA in-
cidence rates of 27.7 per 100,000 women-years (p < 0.001) and of
14.2 for stage IB cancers (p < 0.001). Inviting them six month earlier
(at age 24.5 yrs) led to a more moderate subsequent decrease in stage
IA (12.4, p = 0.001) and IB (9.2, p < 0.001) CxCa incidence rates. No
evidence of a change in stage II or worse cancers (p = 0.163) in this age
group was seen, Fig. 3C and Table 3.
At age 25.5–26.0 yrs the incidence rates of stage IA associated with
inviting women at age 25.0 yrs increased by 10.8 per 100,000 women-
years (p < 0.001). Rates of stage IB CxCa in women aged
25.5–26.0 yrs were similar in cohorts invited from aged 20 yrs and in
cohorts invited at aged 24.5 yrs, Table 3.
After taking into account the gradual increase in incidence rates of
stage II+ cancer in women aged 26 yrs since 2006 (0.7 per year, 95%
CI: 0.22 to 1.1, p = 0.003), inviting women at age 25.0 yrs resulted in a
decrease in stage II+ rates of 4.0 (1.2 to 6.7) per 100,000 women-
years, Table 3.
An increase in stage IA and IB (but no increase in stage II+) CxCa
was seen at age 27 yrs in 2009 (“Jade Goody eﬀect”), Table 3. Although
rates of stage II or worse CxCa at age 27 yrs have decreased with ca-
lendar time, cohorts ﬁrst invited at age 25.0 yrs had an increase in stage
II or worse incidence rates of 4.5 per 100,000 women (95% CI: 1.4 to
Fig. 2. Numbers of cervical cancer (all
stages) and incidence rates per 100,000
women-years in England at ages 20 to
29 years. Legend: Women invited to
screening from age 20 yrs are shown in blue,
women invited at age 25.0 yrs are shown in
orange, women invited at age 24.5 yrs are
shown in green and women for whom we
did not know at which age they received
their ﬁrst invitation are shown in yellow.
Black trend line show incidence rates per
100,000 women-years. (For interpretation
of the references to colour in this ﬁgure le-
gend, the reader is referred to the web ver-
sion of this article.)
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Table 2
Results from the backward step generalised linear model: change in incidence rates per 100,000 women-years (95% conﬁdence intervals) and p-values associated with age at ﬁrst
invitation for screening, calendar year and the Jade Goody eﬀect by age at diagnosis.
Age at
diagnosis
Change in incidence rates associated with calendar year, age at ﬁrst invitation and the Jade Goody eﬀect
Calendar year Invited from age 24a Invited from age 25a Goody eﬀect
Rate per
100,000
95% CI p-Value Rate per
100,000
95% CI p-Value Rate per
100,000
95% CI p-Value Rate per
100,000
95% CI p-Value
20.0–24.5 ‐0.08 (‐0.12 to
‐0.05)
p < 0.001
24.5–25.0 20.3 (15.2 to
25.4)
p < 0.001
25.0–25.5 ‐23.7 (‐32.6 to
‐14.8)
p p < 0.001 43.7 (37.4 to
49.9)
p < 0.001
25.5–26.0 14 (9.9 to
18.1)
p < 0.001
26 0.4 (0.0 to
0.9)
p = 0.059
27 7.3 (2.1 to
14.5)
p = 0.006
28 13.7 (9.8 to
17.6)
p < 0.001 7.9 (2.7 to
13.2)
p = 0.003
29 7.3 (3.1 to
11.4)
p < 0.001 9.9 (4.6 to
15.2)
p < 0.001
a Among the ‘mixed screening group’ we assume that 35% of women born in 1984 will have been invited at age 25 and 70% of those born in 1985. Further we assume that 75% of
women born in 1989 were invited from age 24.5.
Fig. 3. Incidence rates of cervical cancer per
100,000 women-years in England by age and
FIGO stage at diagnosis. Legend: Green trend
lines indicate rates of stage IA, blue trend lines
indicate rates of stage IB and red trend lines rates
of stages II or worse cervical cancer. Note that the
scale on the Y axis in Panel A is diﬀerent to the
rest. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred
to the web version of this article.)
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7.7, p = 0.005).
At age 28–29 yrs a signiﬁcant increase in rates of stage IA CxCa
associated both with the Jade Goody eﬀect and ﬁrst inviting women at
age 25.0 yrs (so that the second invitation would be at age 28.0) was
observed. An increase in rates of stage IB CxCa at age 28 yrs was as-
sociated with inviting women at age 25.0 yrs. At age 29 yrs there was
an increase in stage II or worse cancer associated with the Jade Goody
eﬀect (2.5, 95% CI: 0.2 to 4.8 per 100,000).
In summary, the majority of the increase in CxCa since 2006 is due
to an increase in stage IA and IB cancers associated with the change in
screening policy whereby women are invited for screening at age
25.0 yrs (or 24.5 yrs) instead of from age 20 yrs. An increase in rates of
stage II or worse CxCa associated with inviting women for screening at
age 25.0 yrs was only observed among those aged 27 yrs and could be
an artefact of multiple statistical testing, particularly given that rates of
stage II+ cancer decreased at age 26. Results among those with known
FIGO stage (Supplementary Table 1) support these ﬁndings.
3.4. Comparison of cumulative risk of cervical cancer pre and post change
in age at invitation
The cumulative number of cancers diagnosed at ages 24.5–27.0 yrs
by birth cohort showed that inviting women at age 25.0 or 24.5 yrs
(cohorts born from 1986 onwards) resulted in an average increase of 26
additional cancers per 100,000 women (over 3 years) of which 8 per
100,000 were stage IB and none were stage II or worse.
4. Discussion
An increase detection of prevalent cancer cases is expected when
screening is ﬁrst introduced. Results presented here show a change in
diagnoses at age 24.5–25.5 of stage IA and IB CxCa associated with
changes to the age at ﬁrst invitation. At age 25.0–25.5 the increase
associated with inviting women at age 25.0 instead of from age 20 (43.7
per 100,000 women–years) was greater than the decrease associated
with sending invitations six month earlier (23.7 per 100,000).
Reassuringly no increase in stage II or worse cancers was observed in
women under age 27 yrs. In fact, numbers of stage II or worse cancers
diagnosed at age 24.5–25.0 yrs in 2014 are lower than in any other year
since 2007. The increase in stage II or worse CxCa at age 27 yrs and
29 yrs was unexpected and it is our intention to explore it in detail
elsewhere. However, since the change in rates of stage II CxCa is not
consistent across age groups we cannot rule out that the statistically
‘signiﬁcant’ results are a spurious consequence of multiple-testing. The
increase in diagnoses at age 28 yrs associated with inviting women at
age 25.0 yrs was not anticipated but makes sense in that they are pre-
sumably screen-detected cancers from the second round of screening.
FIGO stage data were missing for between 16 and 20% of cases, we
opted to impute them. This approach will have introduced uncertainty
to the analyses and therefore we have been careful not to over interpret
the results. Reassuringly, results restricted to those with known FIGO
stage were similar. Unfortunately individual-level data on attendance to
cervical screening and vaccination against HPV were not available.
If there was not a public demand to understand the recent increase
in CxCa rates in women aged 20–24, we would have waited a further
three years to allow all cohorts of women in this study the opportunity
to reach age 30 by 2015 and hence be able to estimate cumulative in-
cidence to age 30. However with the available data we have been able
to show that the increase in incidence at age 20–24 is a direct result of
inviting women for their ﬁrst screening test at age 24.5 instead of at age
25 and not an epidemic stemming from lack of prevention.
There could be several operational reasons as to why the rates of
Table 3
Results from the backward step generalised linear model: change in incidence rates per 100,000 women-years (95% conﬁdence intervals) and p-values associated with age at ﬁrst
invitation for screening, calendar year and the Jade Goody eﬀect by age and FIGO stage at diagnosis.
Age at diagnosis FIGO stage Change in incidence rates associated with calendar year, age at ﬁrst invitation and the Jade Goody eﬀect
Calendar year rates (95% CI), p-
values
Invited from age 24a rates (95%
CI), p-values
Invited from age 25a rates (95%
CI), p-values
Jade Goody eﬀect, rates(95% CI),
p-values
20–24.5 IA ‐0.07 (‐0.10 to ‐0.04),
p < 0.001
− − −
IB ‐0.03 (‐0.08 to 0.02),
p = 0.268
− − −
II+ ‐0.03 (‐0.07 to 0.02),
p = 0.241
− − −
24.5–25.0 IA − 15.5 (11.6 to 19.4), p < 0.001 − −
IB − 7.3 (4.3 to 10.2), p < 0.001 − −
II+ − ‐2.4 (‐3.9 to ‐1.0), p = 0.001 − −
25.0–25.5 IA − ‐12.4 (‐19.4 to ‐5.4), p = 0.001 27.7 (23.1 to 32.4), p < 0.001 −
IB − ‐9.2 (‐14.2 to ‐4.1), p < 0.001 14.2 (10.4 to 17.9), p < 0.001 −
II+ − ‐1.2 (‐2.8 to 0.5), p = 0.163 − −
25.5–26.0 IA − − 10.8 (8.1 to 13.5), p < 0.001 −
IB − ‐5.1 (‐8.9 to ‐1.2), p = 0.010 5.2 (1.9 to 8.5), p = 0.002 −
II+ ‐0.1 (‐0.3 to 0.1), p = 0.269 − − −
26 IA 0.5 (0.2 to 0.8), p = 0.002 − − −
IB ‐0.1 (‐0.4 to 0.2), p = 0.492 − − −
II+ 0.7 (0.22 to 1.1), p = 0.003 − ‐4.0 (‐6.7 to ‐1.2), p = 0.004 −
27 IA − − − 3.5 (0.2 to 6.8), p = 0.040
IB − − − 4.1 (0.5 to 7.6), p = 0.024
II+ ‐0.6 (‐1.1 to ‐0.1), p = 0.018 − 4.5 (1.4 to 7.7), p = 0.005 −
28 IA − − 10.2 (7.4 to 12.9), p < 0.001 8.1 (4.1 to 12.1), p < 0.001
IB − − 3.7 (1.3 to 6.1), p = 0.002 −
II+ ‐0.1 (‐0.2 to 0.1), p = 0.331 − − −
29 IA − − 4.7 (1.9 to 7.4), p = 0.001 5.2 (1.8 to 8.6), p = 0.003
IB − − 1.4 (‐1.3 to 4.2), p = 0.306 −
II+ − − − 2.5 (0.2 to 4.8), p = 0.034
The bold indicates p values that were statistically signiﬁcant.
a Among the ‘mixed screening group’ 35% of women born in 1984 will have been invited at age 25 and 70% of those born in 1985. Further we assume that 75% of women born in 1989
were invited from age 24.5.
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cancer at age 25.0–25.5 in 2013 (54.9 per 100,000) were so much
higher than those in 24.5–25.0 yr olds in 2014 (33.4 per 100,000).
Since the policy is still to screen at age 25.0 (but with invitations sent
out 6mths earlier) it may be that the time between invitation and
screening is greater at 24.5 than it was at 25.0. It could also be that
diagnoses following low-grade cytology in women screened at age 24.5
are not made until age 25.
Historically (2007–2012), 66% of CxCa at age 25.0 yrs and 24% at
26–29 yrs were diagnosed in women immediately following their ﬁrst
test (Castanon et al., 2013). Hence it is not surprising to see that most of
the increase in diagnosis under age 30 yrs is stage IA cancers. That the
majority (if not all) of the increase in rates under age 30 yrs is due to
stage I cancer is encouraging since early diagnosis of CxCa increases the
chances that treatment is both curative and fertility preserving. In
England 93% of stage IA1, 88% of stage IA2 and 55% of stage IB1
cancers in women under age 30 yrs are treated conservatively by cone
biopsy or trachelectomy (unpublished data from the Audit of Invasive
Cervical Cancers) and ﬁve year survival for stage I CxCa is estimated to
be 96% (Cancer Research UK, 2014).
Previous research (Landy et al., 2014) estimated that screening from
age 25.0 yrs could lead to an increase of 14 cervical cancers per
100,000 women screened (compared with screening from age 20);
based on an annual cervical intraepithelial neoplasia (CIN) grade 3
progression rate of 0.2% (age 20–24 yrs) to cancer. These excess 14
cancers are attributable to the failure to treat high-grade CIN prior to it
becoming cancer at age 24.5 yrs. Here we estimate an increase of 33
cancers per 100,000 women screened (95 cancers in approximately
292,000 women aged 20.0–27.0 yrs screened each year). The additional
19 cancers per 100,000 women screened, over and above those 14 at-
tributable to a failure to screen from age 20 yrs need understanding.
The dramatic rise in IA cancer at ages 24.5–26.0 yrs and 28 yrs shown
here cannot be solely attributable to early diagnosis at screening of
cancers that would otherwise have been diagnosed a year or two later
since we did not observe any commensurate fall at ages 26 and 27 yrs.
Some of this rise will be explained by the increasing rates (as observed
in Wales and Scotland) which are consistent with published literature
(Foley et al., 2011; Health Protection Agency, 2010) suggesting greater
(and earlier) exposure to HPV. Interestingly, preliminary results from
Sweden (where no change in screening policy has occurred) also show
an increase in stage IA CxCa rates in women under age 35 from 2012 to
2014 (Andrae et al., 2017).
Neither treatment of high-grade CIN following earlier screening,
diagnosis at age 25 of cancers that would have been diagnosed age 26
or 27, nor the increase in underlying risk of HPV infection can fully
explain the increase in rates observed in this study. We hypotheses that
histology may have become more sensitive to micro-invasive cancers
leading to diagnosis of slow-growing (or even regressive) disease at
screening. It is possible, for instance, that more sections of excision
biopsies are being examined for histologic diagnosis and consequently
very small cancers are diagnosed that would otherwise have been re-
corded as high-grade CIN.
One may have expected to see a fall in cervical cancer rates resulting
from HPV vaccination of women aged 14–18 yrs in 2008–2009.
However, we consider it to be too early to draw conclusions regarding
vaccine eﬃcacy from CxCa incidence. It was only from March 2016 that
women immunised (at age 17 or 18) as part of the ﬁrst “vaccine catch-
up” cohort attended screening at age 24.5. These women would have
been aged 22–24 yrs in 2014 but, as we hypothesized previously, since
very few women develop CxCa within 8 years of infection most women
who get CxCa aged 20–24 yrs would have been infected before age 17
(Cuzick et al., 2010).
5. Conclusions
Screening from age 20 yrs, rather than from age 25 yrs, would not
prevent any more cancers from spreading beyond the cervix (stage II or
worse) by age 27 yrs. The substantial increase in stage I cervical cancers
in 24 and 25 year old women, corresponds to changes whereby a high
proportion of women are now screened for the ﬁrst time between ages
24.5 and 25.5 yrs. Previously some of these early stage screen detected
cancers would have been prevented by treatment of high-grade cervical
intraepithelial neoplasia following earlier screening and a few would
have been screen-detected later - at age 26 or 27 yrs. Others may be
slow-growing cancers, some of which could be argued to be over-di-
agnosed.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ypmed.2017.12.002.
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